Rigel Pharmaceuticals partners with PDSA_ITP for ITP awareness campaign this month

Rigel Pharmaceuticals partners with PDSA_ITP for ITP awareness campaign this month
Rigel launches ITP awareness drive

Rigel Pharmaceuticals has initiated a new partnership with the Platelet Disorder Support Association (PDSA_ITP) to support ITP awareness throughout this month.

The campaign is part of #ITPawareness month, encouraging broader understanding and engagement in the immune thrombocytopenia (ITP) community. Rigel Pharmaceuticals aims to drive attention to the disease and its impact through the campaign’s outreach and the support of related causes.

Rigel Pharmaceuticals recently announced the U.S. launch of VEPPANU, the first FDA-approved therapy in its new treatment class, according to a company statement. The firm also reported its Q2 2026 financial results and scheduled an investor webcast to discuss performance earlier this year, as detailed in its latest earnings update. These developments mark continued activity for Rigel in both its product and financial reporting efforts.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.